High Throughput Screening and Implementation (HTS/I) Core
- Co-Leader: Bruce Edwards, Ph.D.
- Provides scientific leadership to the operation. This includes assuring that the latest technologies are incorporated into HTS/I, engaging in outreach with target providers and technology collaborators, and participating in the HTS working group. As biologist, Edwards assures that UNMCMD technological capabilities are state of the art and well-matched to the target pipeline.
- Co-Leader: Mark Carter, MS
- Manages HTS automation/instrumentation, provides documentation, and assists with data analysis/interpretation. He is responsible for daily protocol QA/QC
- Jake Strouse
- UNMCMD chemical biologist, Strouse, manages the compound library in association with HTS/I.
- Jun Chen, Ph.D.
- Screening
- Mark Haynes, Ph.D.
- Screening
- Dominique Perez
- Screening
- Susan Young, MS
- Screening
- Yang Wu, Ph.D.
- Screening
- Terry Foutz, B.S.
- Screening Support
- Peter Simons, Ph.D.
- Screening Support
HTS/I is responsible for validating assays in 384 well format. HTS/I establishes the final assay protocol including automation and QC criteria, in conjunction with AD/A and assay target providers. HTS/I is responsible for all primary and dose-response confirmatory assays, and follow up assays for compounds that enter the screening process through the SMR, purchase, or synthesis. HTS/I is responsible for working with SI to verify the integrity of data collection templates for each project prior to analysis. Innovation: HTS/I is responsible for evaluating emerging flow cytometry technology from the LANL NFCR P41 Center. The chemical biologist is responsible for compound solubility profiling.